This site is intended for health professionals only!

Published on 21 September 2009

Share this story:

Lung cancer drug shows promise

teaser

Pemetrexed maintenance therapy for patients with non-small-cell lung cancer (NSCLC) improves overall and progression-free survival, according to a report in The Lancet.

The Eli Lilly drug was trialled as part of first-line treatment for patients who have received four cycles of platinum-based chemotherapy and not had disease progression.

Author Dr Chandra Belani concludes: “Pemetrexed maintenance therapy is well tolerated and offers significantly improved progression-free and overall survival, making it a new treatment option for patients with advanced non-squamous non-small-cell lung cancer who do not progress after initial induction therapy.”

The phase III study involved 663 patients with advanced NSCLC who had not progressed on four cycles of platinum-based chemotherapy.

They were randomly assigned pemetrexed (500 mg/m2, day 1) plus best supportive care (441 patients) or placebo plus care (222) in 21-day cycles until disease progression.

Primary endpoint was progression-free survival and secondary endpoint overall survival. Standard first-line platinum-based chemotherapy historically provides modest improvements in overall survival.

Copyright Press Association 2009

Pemetrexed



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: